Medical software development and regulatory assessment have different jobs. Developers improve a product; an assessment process examines whether the evidence and controls support a defined intended use. Better tooling can connect those jobs without collapsing one into the other.
That is the useful lens for Scarlet's $50 million Series B. The company is building an assessment organization supported by technology, with designated roles in several jurisdictions. This follow-on to our October 19 coverage examines the operating model: how structured evidence, specialist reviewers and controlled change can make software assessment more useful to a development team.
In This Deep Dive
- What the financing supports and when it was announced
- The boundaries between EU, UK and US assessment roles
- A practical evidence-to-review workflow
- The evidence ladder and complete assessment economics
- The HealthTech Investor's Signal and four developments to watch
What actually happened
Scarlet announced its $50 million Series B on October 12, 2026, not October 26. Headline led the round, with participation from Notion Capital and existing investors Atomico, Creandum, Kindred Capital and Entrepreneurs First. The announcement frames the funding around building a global AI certification body.
The funding is support for an organization and its capabilities. It is not regulatory authorization of an individual customer product. Scarlet's public information describes assessment responsibilities and technology supporting the work of qualified reviewers.
Three regions, three distinct roles
In the European Union, Scarlet operates as an MDR Notified Body within its designated scope. Notified Bodies perform defined conformity-assessment tasks. The relevant legal entity, device scope and assessment route matter; the designation is not blanket authority for every AI application.
In the UK, Scarlet NB UK Ltd is a UK Approved Body under the applicable medical-device framework. MHRA designation and oversight should not be described as the company itself becoming the national regulator.
In the US, Scarlet NB B.V. is recognized as a Third Party Review Organization for eligible 510(k) submissions. Eligibility depends on the program's scope and product codes. The FDA retains oversight and makes the final clearance decision. Third-party review is not direct FDA approval by a private organization.
| Region | Assessment role | Important boundary |
|---|---|---|
| European Union | MDR Notified Body | Defined designation and conformity-assessment scope |
| United Kingdom | UK Approved Body | Applicable UK device and assessment requirements |
| United States | Recognized 510(k) third-party reviewer | Eligible submissions; FDA retains the final decision |
Why this matters now
Software teams benefit from evidence that is organized as the product develops, rather than assembled from memory at the end. Requirements, validation, clinical evaluation and version history become more useful when their relationships are explicit.
This does not mean every software update requires a new submission, or that every review has the same timeline. Change assessment depends on the intended use, nature of the change, device and applicable rules. A useful process helps a team understand which evidence needs updating and which decisions need review.
